id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-0441-0007,FDA,FDA-2024-E-0441,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-19T04:00:00Z,2025,9,2025-09-19T04:00:00Z,,2025-09-19T17:37:07Z,,0,0,09000064b8fb006d
FDA-2024-E-0441-0006,FDA,FDA-2024-E-0441,Determination of Regulatory Review Period for Purposes of Patent Extension; ROCTAVIAN,Notice,Determinations,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2024-12-30T17:34:49Z,2024-31276,0,0,0900006486894bfb
FDA-2024-E-0441-0005,FDA,FDA-2024-E-0441,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-12-27T05:00:00Z,2024,12,2024-12-27T05:00:00Z,,2024-12-27T14:14:56Z,,0,0,09000064868910d6
FDA-2024-E-0441-0004,FDA,FDA-2024-E-0441,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-07-29T04:00:00Z,2024,7,2024-07-29T04:00:00Z,,2024-07-29T16:07:19Z,,0,0,09000064865ffc85
FDA-2024-E-0441-0003,FDA,FDA-2024-E-0441,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2024-04-26T04:00:00Z,2024,4,2024-04-26T04:00:00Z,,2024-04-26T13:34:12Z,,0,0,09000064864f2b53
FDA-2024-E-0441-0002,FDA,FDA-2024-E-0441,"Patent Term Extension Application for ROCTAVIAN® (valoctocogene roxaparvovec-rvox), Patent No. 11,406,690",Other,Application,2024-01-26T05:00:00Z,2024,1,2024-01-26T05:00:00Z,,2024-01-26T20:43:56Z,,0,0,09000064863b9f33
FDA-2024-E-0441-0001,FDA,FDA-2024-E-0441,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-26T05:00:00Z,2024,1,2024-01-26T05:00:00Z,,2024-01-26T20:43:49Z,,0,0,09000064863b9f31